MedTrace Logo

A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study

NCT01036165 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2013-08-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the RebiSmart™ for

* ease of use
* multiple domains related to subject's acceptability and satisfaction
* reliability of the correct function for self-injection of Rebif® 44 mcg sc tiw in subjects with RMS.

Conditions

Interventions

DEVICE

RebiSmart™

The RebiSmart™ autoinjector contains Rebif® 132 mcg multidose cartridges for sc injection.

Sponsors & Collaborators

Principal Investigators

  • Fernando Dangond, MD · EMD Serono

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01036165 on ClinicalTrials.gov